PharmaShots Weekly | Oct 19, 2026 Edition - Join the PharmaShots Family of 20000+ Subscribers

Welcome to PharmaShots Weekly

Oct 19, 2026 Edition

PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.

Rona Licenses ALK7 RNAi Therapy to Roche

Prelude and Lilly Partner on Breast Cancer Trial

Zealand, Generate Sign $1.2B Metabolic Drug Deal

Pfizer Enters Sec61 Drug Discovery With Enodia

Stay Curious.

Stay informed!

Stay ahead with PharmaShots Weekly! 

Monday Briefing

Cover Story

•	Vir Biotechnology and Gilead Sign $1.9B T-Cell Engager Discovery Deal

Strategic Deals & Partnerships

•	Rona Therapeutics and Roche: ALK7-Targeting RNAi Therapy for Obesity

•	Prelude Therapeutics and Lilly: KAT6A Degrader Combination Trial

•	Zealand Pharma and Generate Biomedicines: AI-Engineered Protein Therapeutics

•	Nxera Pharma and Synmosa: QUVIVIQ Expansion Across Eight Asia-Pacific Markets

•	Enodia Therapeutics and Pfizer: Sec61-Targeting Small Molecules

•	AstraZeneca and insitro: AI-Driven Drug Discovery Collaboration

Mergers & Acquisitions

•	Galderma to Acquire ZO Skin Health for $1.5B

•	Labcorp to Acquire Select BioReference Health Assets

Clinical Trials Watch

•	BMS' Admilparant Meets Phase 3 Endpoint in Idiopathic Pulmonary Fibrosis

PharmaShots Weekly | Oct 19, 2026 Edition

Keep reading

More issues

PharmaShots Weekly | Oct 12, 2026 Edition

Meet the Leaders Shaping Pharma Partnerships